Several cheaper alternatives to Wegovy exist, ranging from the same active ingredient at a lower price to older weight loss medications that cost a fraction as much. Wegovy’s list price sits at $499 per month without insurance, but depending on your situation, you may be able to get effective weight loss treatment for as little as $25 to $199 per month.
The tradeoff is straightforward: the less you pay, the less weight you’re likely to lose. Wegovy produces about 15.8% body weight loss over 68 weeks in clinical trials. The cheapest alternatives deliver closer to 2% to 5%. Your best option depends on your budget, insurance status, and how much weight you need to lose.
Compounded Semaglutide: Same Drug, Lower Price
Compounded semaglutide is the closest thing to a direct substitute. It uses the same active ingredient as Wegovy but is mixed by specialty pharmacies rather than manufactured by Novo Nordisk. Telehealth providers like Hims, Henry Meds, and others offer compounded semaglutide programs for roughly $179 to $299 per month, compared to Wegovy’s $499 cash price.
There’s an important caveat. The FDA has raised concerns about compounded versions, particularly those using salt forms of semaglutide (like semaglutide sodium or semaglutide acetate) rather than the exact form in the approved drug. The FDA says it doesn’t have evidence that these salt forms share the same properties as the branded version, and it isn’t aware of a lawful basis for using them in compounding. That doesn’t mean every compounded product is unsafe, but it does mean you’re accepting more uncertainty than you would with the brand-name drug. If you go this route, look for providers that are transparent about their pharmacy sources and ingredient forms.
Novo Nordisk’s Own Savings Programs
If you have commercial insurance that covers Wegovy, Novo Nordisk offers a savings card that drops your copay to $25 per month for a 28-day supply. That makes it the cheapest option by far, but there are two hurdles: your insurance has to cover the drug, and you have to qualify.
Most insurers require prior authorization before they’ll approve Wegovy. A typical set of criteria, based on CVS Caremark’s policy, requires that you’re 18 or older, have a BMI of 30 or above (or 27 or above with a condition like high blood pressure, type 2 diabetes, or high cholesterol), and have already spent at least six months in a structured weight management program involving diet changes, exercise, and behavioral support. That six-month requirement catches many people off guard and can delay coverage significantly. For adolescents aged 12 to 17, the threshold is a BMI at or above the 95th percentile for their age and sex.
Zepbound: More Weight Loss, Same Price Tier
Zepbound (tirzepatide) isn’t cheaper than Wegovy at list price. Both cost $499 per month without insurance, with Zepbound’s lowest starter dose available at $349. But Zepbound delivers substantially more weight loss, which makes it a better value per pound if cost is similar for you after insurance.
In a head-to-head clinical trial, people on Zepbound lost about 50 pounds, or 20.2% of their body weight, compared to 33 pounds (13.7%) for those on Wegovy. That’s roughly 50% more weight loss. Zepbound works by targeting two gut hormones instead of just one, which appears to account for the difference. If your insurance covers one but not the other, or if the copay differs, this comparison matters.
Saxenda: An Older Injectable at a Lower Cost
Saxenda (liraglutide) is an older daily injection that works through the same biological pathway as Wegovy. It’s less effective: people on Saxenda lost about 6.4% of their body weight over 68 weeks, compared to 15.8% on Wegovy. That’s less than half the result.
The main advantage is that Saxenda has been on the market longer, which means some insurers cover it more readily, and it’s occasionally available at a lower out-of-pocket cost. The daily injection schedule is also a downside compared to Wegovy’s once-weekly shot. For someone who can’t access or afford Wegovy, Saxenda still produces meaningful weight loss, just at a more modest level.
Oral Prescription Medications
Two FDA-approved oral medications for weight loss cost significantly less than any injectable. Contrave, which combines an antidepressant with an addiction medication to reduce cravings, is available for as little as $99 per month through the manufacturer’s discount program. It produces about 4% to 5% total body weight loss over a year. For someone weighing 250 pounds, that’s roughly 10 to 12 pounds.
Qsymia, which pairs a low-dose stimulant with an anti-seizure drug that suppresses appetite, performs better at 7% to 9% body weight loss. That’s still well below Wegovy’s results, but it costs far less and doesn’t require injections. Both medications come with their own side effect profiles and aren’t appropriate for everyone, so they require a prescription and monitoring.
Phentermine on its own is one of the oldest and cheapest weight loss drugs available, though it’s only approved for short-term use (typically 12 weeks). It’s a stimulant that suppresses appetite and can be very inexpensive, sometimes under $30 per month as a generic.
Metformin: The Budget Off-Label Option
Metformin is a diabetes drug that some doctors prescribe off-label for weight management. It costs as little as $4 to $20 per month as a generic, making it the most affordable prescription option by a wide margin. The weight loss results, however, are modest.
In the largest study examining metformin for weight loss in people without diabetes, participants lost an average of about 4.6 pounds (2.1 kg) over nearly three years at a dose of 1,700 mg per day. That’s a small amount, but there’s a meaningful subgroup effect: about 30% of people who took metformin lost more than 5% of their body weight in the first year, and those responders maintained an average loss of 6.2% after 15 years of follow-up. So while the average result is underwhelming, some people respond quite well.
Doctors typically start metformin at a low dose and work up to 1,500 mg per day or more, using extended-release versions to minimize the digestive side effects (nausea, diarrhea) that are common in the first few weeks. It’s not going to replicate Wegovy’s results, but at its price point, it’s an option worth discussing with your doctor if cost is the primary barrier.
When Generics Might Arrive
Novo Nordisk’s U.S. patent on semaglutide is set to expire in 2032, but the timeline for actual generic availability shifted in late 2024 when Novo Nordisk settled patent lawsuits with several major generic manufacturers, including Mylan (Viatris), Sun Pharmaceutical, Dr. Reddy’s Laboratories, and Apotex. The settlement terms are confidential, but these deals typically include agreed-upon dates when generics can launch, which could be before the 2032 patent expiration. Until then, the options above are what’s available.
Comparing Your Options Side by Side
- Wegovy with savings card: ~$25/month (requires commercial insurance coverage)
- Compounded semaglutide: $179 to $299/month (same ingredient, less regulatory oversight)
- Zepbound: $349 to $499/month (more weight loss, similar price tier)
- Saxenda: varies, often less than Wegovy (about 6.4% weight loss vs. 15.8%)
- Contrave: ~$99/month (4% to 5% weight loss, oral)
- Qsymia: varies (7% to 9% weight loss, oral)
- Metformin: $4 to $20/month (modest average loss, some people respond well)
The gap between Wegovy’s results and cheaper alternatives is real, but so is the gap in price. For many people, a less expensive medication that produces moderate weight loss is more practical than a drug they can’t afford to stay on long-term, especially since weight tends to return when any of these medications are stopped.